Eliminating the type I restriction endonuclease from Pseudomonas aeruginosa PAO1 for optimized phage isolation

Ellie J Tong1, Kate A Bickerton1, Alina J Creber1

  • 1Biosciences, Faculty of Health and Life Sciences, University of Exeter, Stocker Road, Exeter EX4 4QD, UK.

PubMed

Insights

Researchers enhanced phage therapy by engineering a Pseudomonas aeruginosa host. Deleting the HsdR enzyme increased phage isolation and production efficiency, crucial for treating multidrug-resistant infections.

Area of Science:

  • Microbiology
  • Bacteriology
  • Virology

Background:

  • Phage therapy offers a promising alternative for combating multidrug-resistant bacterial infections.
  • High host specificity of bacteriophages necessitates matching phages to specific bacterial strains for effective treatment.
  • Current methods for phage isolation and production require extensive phage libraries and multiple bacterial hosts.

Purpose of the Study:

  • To develop a more promiscuous bacterial host for improved bacteriophage isolation and propagation.
  • To enhance the efficiency of phage therapy by optimizing the bacterial host system.

Main Methods:

  • Deletion of the type I restriction endonuclease (HsdR) gene from *Pseudomonas aeruginosa* PAO1.
  • Evaluation of the modified *P. aeruginosa* strain as a host for phage isolation and propagation on solid and liquid media.
  • Quantification of phage yields from environmental samples using wild-type and modified PAO1 strains.

Main Results:

  • The HsdR-deleted *P. aeruginosa* strain demonstrated more than double the efficiency of phage propagation on solid media.
  • Improved yields of difficult-to-propagate phages were achieved in liquid culture using the modified host.
  • The engineered strain yielded seven times more phages from freshwater samples compared to the wild-type strain.

Conclusions:

  • Engineering *Pseudomonas aeruginosa* by deleting HsdR significantly enhances its utility as a host for bacteriophage isolation and propagation.
  • This optimized bacterial host is a critical advancement for developing robust phage libraries and streamlining phage production for clinical phage therapy.
  • The findings pave the way for more efficient and effective phage-based treatments against bacterial infections.